X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (965) 965
Publication (201) 201
Book Review (11) 11
Book / eBook (2) 2
Conference Proceeding (2) 2
Book Chapter (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (754) 754
adenine - analogs & derivatives (663) 663
tenofovir (511) 511
index medicus (472) 472
male (388) 388
female (381) 381
pharmacology & pharmacy (376) 376
organophosphonates - pharmacokinetics (349) 349
animals (326) 326
adenine - pharmacokinetics (324) 324
organophosphonates - administration & dosage (289) 289
hiv infections - drug therapy (285) 285
pharmacokinetics (284) 284
adult (273) 273
adenine - administration & dosage (261) 261
organophosphonates - therapeutic use (244) 244
adenine - therapeutic use (242) 242
infectious diseases (211) 211
organophosphonates (208) 208
middle aged (200) 200
anti-hiv agents - pharmacokinetics (174) 174
anti-hiv agents - administration & dosage (166) 166
hiv (165) 165
adenine - adverse effects (163) 163
organophosphonates - adverse effects (161) 161
organophosphonates - pharmacology (160) 160
antiviral agents (158) 158
anti-hiv agents - therapeutic use (145) 145
emtricitabine (144) 144
antiviral agents - pharmacokinetics (143) 143
cytosine - analogs & derivatives (143) 143
microbiology (141) 141
deoxycytidine - analogs & derivatives (139) 139
drug therapy, combination (133) 133
antiviral agents - therapeutic use (128) 128
adenine - pharmacology (121) 121
virology (116) 116
immunology (114) 114
organophosphonates - chemistry (111) 111
anti-hiv agents - adverse effects (108) 108
adenine - blood (106) 106
infection (106) 106
organophosphonates - blood (105) 105
virus diseases (104) 104
drug interactions (103) 103
cidofovir (100) 100
rats (99) 99
mice (97) 97
treatment outcome (95) 95
safety (94) 94
antiviral agents - administration & dosage (92) 92
hiv-1 - drug effects (92) 92
therapy (92) 92
administration, oral (90) 90
antiretroviral therapy (90) 90
organophosphorus compounds - pharmacokinetics (89) 89
reverse transcriptase inhibitors - pharmacokinetics (87) 87
lamivudine (86) 86
drug therapy (85) 85
disoproxil fumarate (84) 84
deoxycytidine - administration & dosage (83) 83
antiviral agents - pharmacology (81) 81
adolescent (75) 75
in-vitro (74) 74
hiv infection (72) 72
hiv infections - prevention & control (72) 72
research (72) 72
adefovir (71) 71
article (71) 71
hiv infections - virology (71) 71
reverse transcriptase inhibitors - therapeutic use (69) 69
dose-response relationship, drug (67) 67
prevention (67) 67
anti-hiv agents - pharmacology (66) 66
drug combinations (66) 66
tissue distribution (66) 66
health aspects (65) 65
organophosphorus compounds - therapeutic use (65) 65
reverse transcriptase inhibitors - administration & dosage (65) 65
viral load (65) 65
aids (64) 64
human immunodeficiency virus--hiv (64) 64
dosage and administration (63) 63
young adult (63) 63
analysis (62) 62
pharmacology (62) 62
cytosine - pharmacokinetics (61) 61
cytosine - therapeutic use (61) 61
efficacy (61) 61
antiviral agents - adverse effects (60) 60
metabolism (60) 60
hiv-1 (58) 58
human-immunodeficiency-virus (57) 57
chemistry, medicinal (55) 55
biological availability (54) 54
research article (54) 54
aids/hiv (53) 53
antiviral activity (53) 53
area under curve (53) 53
deoxycytidine - therapeutic use (53) 53
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (946) 946
Spanish (7) 7
Chinese (5) 5
French (4) 4
German (3) 3
Korean (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
AIDS, ISSN 0269-9370, 09/2007, Volume 21, Issue 14, pp. 1899 - 1907
Objectives: To describe first dose and steady state antiretroviral drug exposure in the female genital tract. Design: Non-blinded, single center, open-label... 
Women | Genital tract | HIV | Prophylaxis | Sexual transmission | Pharmacokinetics | Antiretroviral therapy | genital tract | INFECTIOUS DISEASES | sexual transmission | antiretroviral therapy | EMTRICITABINE | IMMUNOLOGY | CEREBROSPINAL-FLUID | prophylaxis | BACTERIAL VAGINOSIS | PROTEASE INHIBITOR | TRICHOMONAS-VAGINALIS | HIV-INFECTION | THERAPY | VIROLOGY | LIQUID-CHROMATOGRAPHY | SIMIAN IMMUNODEFICIENCY VIRUS | pharmacokinetics | MACAQUES | women | Lamivudine - administration & dosage | Humans | Deoxycytidine - blood | Zidovudine - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Genitalia, Female - metabolism | Emtricitabine | HIV Infections - blood | HIV Protease Inhibitors - blood | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Administration, Oral | Anti-Retroviral Agents - pharmacokinetics | Deoxycytidine - administration & dosage | Lopinavir | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Pyrimidinones - blood | Anti-Retroviral Agents - administration & dosage | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Zidovudine - blood | Deoxycytidine - analogs & derivatives | Reverse Transcriptase Inhibitors - blood | Zidovudine - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | HIV Infections - drug therapy
Journal Article
AIDS, ISSN 0269-9370, 01/2014, Volume 28, Issue 1, pp. 59 - 66
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 08/2013, Volume 63, Issue 4, pp. 449 - 455
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 12/2012, Volume 51, Issue 12, pp. 809 - 822
Journal Article
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 04/2011, Volume 56, Issue 5, pp. 412 - 419
BACKGROUND:Few data are available describing atazanavir exposure during pregnancy, especially when used in combination with tenofovir, whose coadministration... 
pharmacokinetics | HIV | atazanavir | tenofovir | mother to child transmission | pregnancy | INDINAVIR | INFECTIOUS DISEASES | EFFICACY | SAFETY | SAQUINAVIR | IMMUNOLOGY | NELFINAVIR | WOMEN | LAMIVUDINE | ZIDOVUDINE | LOPINAVIR EXPOSURE | RITONAVIR | HIV Infections - prevention & control | Pregnancy Complications, Infectious - virology | Prospective Studies | Humans | Pyridines - pharmacokinetics | Postpartum Period | Reverse Transcriptase Inhibitors - administration & dosage | Pregnancy Trimester, Third | Anti-HIV Agents - administration & dosage | Tenofovir | Reverse Transcriptase Inhibitors - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Female | HIV Infections - transmission | Drug Therapy, Combination | Adenine - analogs & derivatives | Pyridines - administration & dosage | Drug Administration Schedule | Ritonavir - administration & dosage | HIV-1 - drug effects | HIV Infections - virology | Oligopeptides - pharmacokinetics | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Pregnancy | Organophosphonates - administration & dosage | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Pregnancy Complications, Infectious - drug therapy | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Drug Monitoring | Infectious Disease Transmission, Vertical - prevention & control
Journal Article
Journal Article
JAMA, ISSN 0098-7484, 07/2002, Volume 288, Issue 2, pp. 169 - 180
CONTEXT Management of antiretroviral treatment failure in patients receiving protease inhibitor (PI)–containing regimens is a therapeutic challenge. OBJECTIVE... 
MEDICINE, GENERAL & INTERNAL | DRUG-INTERACTIONS | COMBINATION THERAPY | VIROLOGICAL FAILURE | IMMUNODEFICIENCY-VIRUS TYPE-1 | RESISTANCE | SOCIETY-USA PANEL | HIV-1-INFECTED PATIENTS | PLUS INDINAVIR | HIV-INFECTED ADULTS | CLINICAL PHARMACOKINETICS | Humans | Drug Resistance, Viral | Male | Benzoxazines | Saquinavir - therapeutic use | Viral Load | Reverse Transcriptase Inhibitors - adverse effects | HIV Infections - immunology | Oxazines - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Adenine - therapeutic use | HIV Protease Inhibitors - pharmacokinetics | Treatment Failure | Adult | Anti-HIV Agents - therapeutic use | Female | Dideoxynucleosides - therapeutic use | Reverse Transcriptase Inhibitors - therapeutic use | HIV Protease Inhibitors - adverse effects | Indinavir - pharmacokinetics | Nelfinavir - therapeutic use | Adenine - analogs & derivatives | Double-Blind Method | Anti-HIV Agents - adverse effects | Proportional Hazards Models | CD4 Lymphocyte Count | Adenine - pharmacokinetics | HIV Protease Inhibitors - therapeutic use | Disease Progression | Sulfonamides - pharmacokinetics | Antiretroviral Therapy, Highly Active | Dideoxynucleosides - pharmacokinetics | Organophosphonates | Sulfonamides - therapeutic use | Oxazines - therapeutic use | Anti-HIV Agents - pharmacokinetics | Saquinavir - pharmacokinetics | Carbamates | HIV Infections - drug therapy | Nelfinavir - pharmacokinetics | Indinavir - therapeutic use | Evaluation | Protease inhibitors | Drug therapy | HIV infection | Medical research | Human immunodeficiency virus | HIV
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 05/2009, Volume 53, Issue 5, pp. 1937 - 1943
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
IN-VITRO | HIV | DIDANOSINE | CARBOVIR TRIPHOSPHATE | REVERSE-TRANSCRIPTASE | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | P-GLYCOPROTEIN EXPRESSION | LOPINAVIR/RITONAVIR | BLOOD MONONUCLEAR-CELLS | PROTEASE INHIBITORS | MASS-SPECTROMETRY | Lamivudine - administration & dosage | Area Under Curve | Humans | Middle Aged | Male | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Reverse Transcriptase Inhibitors - pharmacokinetics | Drug Interactions | HIV Protease Inhibitors - pharmacokinetics | Adult | Female | Drug Therapy, Combination | Dideoxynucleosides - administration & dosage | Adenine - analogs & derivatives | Cross-Sectional Studies | Ritonavir - administration & dosage | HIV-1 - drug effects | HIV Infections - virology | Lopinavir | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | Lamivudine - pharmacokinetics | Adenine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Dideoxynucleosides - pharmacokinetics | Organophosphonates - administration & dosage | Pilot Projects | Pyrimidinones - pharmacokinetics | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | HIV Infections - drug therapy | Pyrimidinones - administration & dosage | Longitudinal Studies | Index Medicus | Pharmacology
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 08/2013, Volume 57, Issue 8, pp. 3994 - 3997
Journal Article